For the two major providers Eli Lilly & Novo Nordisk, they will enjoy with much larger unit sales to benefit them. Although the prices look much lower, the actual difference is much less as the US$1,000+ list price include substantial rebate to HBM firms. More importantly, lower prices are coming anyway as the initial research cost are recovered in the last 2-3 years huge sales and that lower price point is a must to penetrate the mass market.
Therefore, a certain reasonable price drops to gain a market size up to 5 times bigger than the current one is a good deal for drug companies. Novo Nordisk stock price has been hit by several management problems of its own to low level that may take longer to resolve. Eli Lilly has been doing much better and has clear advantage and more market share on this important new GLP-1 drug market. Eli Lilly’s share price is also lower than its peak and underperform the broader market due to this government negotiation uncertainty. With this new deal to remove related uncertainties, its stock price could extend its recent rebound and challenge record high level soon and investors should take this chance to accumulate its stocks for long-term gain.
陳俊文(Norman)是一位獨立投資策略師,擁有超過30年專業投資經驗,曾在家族辦公室、銀行、精品基金公司、財富管理公司工作。在其職業生涯中,管理過多種資產,包括全球股票投資組合、多元資產投資組合、基金中的基金和可轉換債券基金。Norman對全球金融市場及多種投資資產具深入了解,包括全球股票、債券(高等級、高收益、混合、可轉換)、衍生性商品(選擇權、認股權證、掉期等)以及各類多頭和多頭產品對沖基金。他經常接受媒體採訪,並曾擔任多家大專院校專業金融課程的客座講師。











